Across TCGA pan-cancer cohorts, RNF44 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RNF44 data layer compared with 26 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RNF44 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RNF44 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
LUAD, SARC, and UCEC are the cancer types where RNF44 Mutation most reproducibly stratifies survival.